StockGlow

Adagene Inc. (ADAG)

Develops antibody drugs to treat cancer patients in China.

$3.73+0.06%Healthcare
Compare ADAG with
StockGlow Score
80
Bullish
BearishBullish
1 year ago+94.3%

The outlook

Adagene trades at $3.73 with six analysts issuing a Strong Buy consensus. The stock sits roughly two-thirds of the way between its 52-week low and high, showing mixed momentum against its moving averages. Analysts' average price target sits approximately 188% above the current price.

What’s behind the score

Analyst consensusStrong Buy — 1.3 avg of 6 analysts
Price trendMixed vs its moving averages
52-week range68% of the way from its 52-week low to high
Price targetAvg target +188% vs current price

Analyst price target

~12-month · 6 analysts
$10.74average target+188.0% vs now
Now $3.73
Low $7.00High $17.45

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$246.5M
52-wk high
$4.85
52-wk low
$1.30
50-day avg
$3.73
200-day avg
$2.93
Trailing P/E
—

Similar stocks

CNTBConnect Biopharma Holdings Limited$2.08-0.95%ALGSAligos Therapeutics, Inc.$4.25+4.17%PHVSPharvaris N.V.$33.65-0.96%FTHFaeth Therapeutics, Inc.$29.13-0.38%ADXNAddex Therapeutics Ltd$5.89+0.00%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy